(TARS) – Management Comments
-
Tarsus Pharmaceuticals (TARS) Announces Positive Results of TP-03 Phase 2b/3 Saturn-1 Trial
-
Tarsus Pharmaceuticals (TARS) Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03
Back to TARS Stock Lookup